Nevirapine toxicity - implications for management of South African patients
| dc.contributor.author | Wood, Robin | |
| dc.date.accessioned | 2019-03-27T13:31:36Z | |
| dc.date.available | 2019-03-27T13:31:36Z | |
| dc.date.issued | 2005 | |
| dc.date.updated | 2019-03-19T09:04:35Z | |
| dc.description.abstract | Nevirapine was the first non-nucleoside drug (NNRTI) to be approved by the Federal Drug Administration (FDA) for use in combination therapy of HIV-1 infection in 1996. It has been approved for use in children of 2 months or older, and following the publication of the HIVNET 012 study in Uganda1 has been widely used as single-dose prophylaxis for prevention of mother-to-child HIV transmission (MTCT) in resource-poor settings. Early in nevirapine development, a cutaneous hypersensitivity rash occurring in the first 4 weeks of therapy was recognised as a common side-effect, and registration studies reported clinical hepatitis in approximately 1% of individuals.2 Despite these recognised toxicities, cheap generic formulations, including fixed-dose combinations, have been manufactured in India and Brazil, making nevirapine one of the most commonly prescribed antiretrovirals worldwide. | |
| dc.identifier.apacitation | Wood, R. (2005). Nevirapine toxicity - implications for management of South African patients. <i>South African Medical Journal</i>, http://hdl.handle.net/11427/29955 | en_ZA |
| dc.identifier.chicagocitation | Wood, Robin "Nevirapine toxicity - implications for management of South African patients." <i>South African Medical Journal</i> (2005) http://hdl.handle.net/11427/29955 | en_ZA |
| dc.identifier.citation | Wood, R. (2005). Nevirapine toxicity-implications for management of South African patients: original article. South African Medical Journal, 95(4), p-253. | |
| dc.identifier.ris | TY - AU - Wood, Robin AB - Nevirapine was the first non-nucleoside drug (NNRTI) to be approved by the Federal Drug Administration (FDA) for use in combination therapy of HIV-1 infection in 1996. It has been approved for use in children of 2 months or older, and following the publication of the HIVNET 012 study in Uganda1 has been widely used as single-dose prophylaxis for prevention of mother-to-child HIV transmission (MTCT) in resource-poor settings. Early in nevirapine development, a cutaneous hypersensitivity rash occurring in the first 4 weeks of therapy was recognised as a common side-effect, and registration studies reported clinical hepatitis in approximately 1% of individuals.2 Despite these recognised toxicities, cheap generic formulations, including fixed-dose combinations, have been manufactured in India and Brazil, making nevirapine one of the most commonly prescribed antiretrovirals worldwide. DA - 2005 DB - OpenUCT DP - University of Cape Town J1 - South African Medical Journal LK - https://open.uct.ac.za PY - 2005 T1 - Nevirapine toxicity - implications for management of South African patients TI - Nevirapine toxicity - implications for management of South African patients UR - http://hdl.handle.net/11427/29955 ER - | en_ZA |
| dc.identifier.uri | http://hdl.handle.net/11427/29955 | |
| dc.identifier.vancouvercitation | Wood R. Nevirapine toxicity - implications for management of South African patients. South African Medical Journal. 2005; http://hdl.handle.net/11427/29955. | en_ZA |
| dc.language.iso | eng | |
| dc.source | South African Medical Journal | |
| dc.source.uri | http://www.samj.org.za/index.php/samj | |
| dc.title | Nevirapine toxicity - implications for management of South African patients | |
| dc.type | Journal Article |